HomeCONGRESS

CONGRESS

View Category
Day 1

EUROMAX: Bivalirudin during transport to primary angioplasty

The HORIZONS AMI trial showed the usefulness of bivalirudin in reducing mortality and bleeding compared with the...
solaci -
Learn More
Day 1

SYNTAX II: multiple vessels using iFR / FFR and IVUS

This study is still in progress and includes patients using SYNTAX II score based on functional invasive...
solaci -
Learn More
Day 1

BIOFLOW II. Stent eluidor de sirolimus com polímero degradável.

This non-inferiority design study compared the sirolimus-eluting stent with biodegradable polymer versus everolimus-eluting stent with permanent polymer...
solaci -
Learn More
Day 3

TRANSLATE-POPS: Routine measurement of platelet aggregation generates a minimal impact on the treatment setting

The high platelet reactivity is associated with adverse events after stent implantation. Current guidelines consider the measurement...
solaci -
Learn More
Day 3

TATORT-NSTEMI: Routinely thromboaspiration in patients with non ST-elevation AMI

Thromboaspiration in patients with ST-elevation is being questioned while in patients without elevation this strategy has not...
solaci -
Learn More
Day 3

REPRISE II: LOTUS valve for percutaneous aortic valve replacement

The aim of this study was to evaluate the safety and efficacy of the new device in...
solaci -
Learn More
Day 3

GIANT: Evaluation of the genetic profile of CYP2C19 in patients undergoing primary angioplasty

The aim of this study was to evaluate the clinical impact resistance thienopyridines through genetic analysis of...
solaci -
Learn More
Day 3

HYBRID: Hybrid revascularization in patients with multi-vessel

We included 200 patients (100 with hybrid revascularization and 100 with conventional surgery). The complete revascularization rate...
solaci -
Learn More